Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus Oncology, Inc. (formerly Coherus BioSciences, Inc.) on May 29, 2025. The filing documents a corporate name change and related amendments to the company's governing documents.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance changes and does not contain financial performance data.
Material Changes
- Corporate Name Change: Effective May 29, 2025, the company changed its name from Coherus BioSciences, Inc. to Coherus Oncology, Inc.
- Governing Documents: The company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation and adopted Second Amended and Restated Bylaws to reflect the new name.
- Stock Trading: The common stock continues to trade on The Nasdaq Global Market under the symbol "CHRS". The CUSIP number remains unchanged.
- Shareholder Approval: The name change did not require stockholder approval and does not affect stockholder rights.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document focuses solely on the administrative execution of the name change.
Investor Verification Checklist
- Verify the effective date of the name change (May 29, 2025) in corporate registries.
- Confirm that the stock ticker symbol remains "CHRS" on The Nasdaq Global Market.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) and Second Amended and Restated Bylaws (Exhibit 3.2) for any clauses beyond the name change.
- Check the press release dated May 30, 2025 (Exhibit 99.1) for additional strategic context regarding the rebranding.